New Stock News | Hemei Pharmaceutical Passes HKEX Hearing, Cumulative Loss of RMB 253 Million Over Two Years, Core Product Just Beginning Commercialization

Zhitong Finance APP has learned that according to the disclosure by the Hong Kong Stock Exchange on October 20, Ganzhou Hemei Pharmaceutical Co., Ltd. (referred to as: Hemei Pharmaceutical) has passed the listing hearing for the Main Board of the Hong Kong Stock Exchange, with SDIC Securities International as the sole sponsor.